Red cell distribution width in anemic patients undergoing transcatheter aortic valve implantation

Table 2 Clinical outcome of patients undergoing transcatheter aortic valve replacement according to the presence of baseline anemia n (%)

	Entire cohort (n = 376)	Anemia (n = 239)	No anemia (n = 137)	P-value
Vascular complications
Any vascular complications	34 (9.0)	24 (10.0)	10 (7.3)	0.372
Minor vascular complications	20 (5.3)	14 (5.9)	6 (4.4)	0.639
Major vascular complications	4 (1.1)	3 (1.3)	1 (0.7)	0.633
Bleeding complications
Any bleeding complications	45 (12.0)	27 (11.3)	18 (13.1)	0.596
Life-threatening bleeding	20 (5.3)	12 (5.0)	8 (5.8)	0.732
Minor bleeding	21 (5.6)	12 (5.0)	9 (6.6)	0.529
Major bleeding	4 (1.1)	3 (1.3)	1 (0.7)	0.633
Percutaneous closure device failure	10 (2.7)	7 (2.9)	3 (2.2)	0.668
Acute kidney injury	75 (31.4)	60 (25.1)	15 (10.9)	0.001
Acute kidney injury stage I	44 (11.7)	33 (13.8)	11 (8.0)	0.093
Acute kidney injury stage II	1 (0.3)	1 (0.4)	0 (0.0)	0.636
Acute kidney injury stage III	30 (8.0)	26 (10.9)	4 (2.9)	0.007
Need for dialysis	22 (5.9)	18 (7.5)	4 (2.9)	0.069
Myocardial infaction	1 (0.3)	1 (0.4)	0 (0.0)	0.448
Stroke	10 (2.7)	7 (2.9)	3 (2.2)	0.668
Conversion to open surgery	8 (2.1)	6 (2.5)	2 (1.5)	0.497
Sepsis	23 (6.1)	20 (8.4)	3 (2.2)	0.016
Endocarditis	0 (0.0)	0 (0.0)	0 (0.0)
Need for pacemaker	77 (20.5)	51 (21.3)	26 (19.0)	0.585
Length of stay > 14 d	235 (62.5)	152 (63.6)	83 (60.6)	0.561
30-d mortality	27 (7.2)	22 (9.2)	5 (3.6)	0.045